Metraipolis › archive › dc_5dab14825ea3

Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy — Europe PMC PMID:42756147

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42756147
DOI
10.3389/fimmu.2026.1879839
License (as archived)
solo-consultazione
Archived
2026-10-16T05:52:11.036Z
SHA-256 of the archived text
886cdc1958d916aea7a0e83e6d7fa8bb6c8f15b6247277a4f148bfbb071e40d3
Stable URL of this page
https://metraipolis.com/documento/dc_5dab14825ea3

How to cite

Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy — Europe PMC PMID:42756147 — Europe PMC (en), https://europepmc.org/article/MED/42756147 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5dab14825ea3 (Metraipolis archive dc_5dab14825ea3, sha256 886cdc1958d916aea7a0e83e6d7fa8bb6c8f15b6247277a4f148bfbb071e40d3)
BibTeX
@misc{dc5dab14825ea3,
  title = {Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy — Europe PMC PMID:42756147},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42756147},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5dab14825ea3; sha256 886cdc1958d916aea7a0e83e6d7fa8bb6c8f15b6247277a4f148bfbb071e40d3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42756147. Agents can read the archived copy with the MCP tool read_document.